Clinical trials: Hepatobiliary Disorders
Non-alcoholic Fatty Liver Disease
Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
In this multicentric, double-blind, randomized,placebo-controlled study, the investigators hypothesized that rifaximin might act on Gram-negative bacteria and intestinal bacterial overgrowth(IBO) thereby inhibiting…
- Trial name
- NCT02884037
- Testing
- Rifaximin group 1
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Non-Alcoholic Fatty Liver Disease
The Influence of SARS-CoV-2 Lifestyle Changes on Non-alcoholic Fatty Liver Disease Evolution
Unhealthy lifestyle represents a key element fueling the non-alcoholic fatty liver disease (NAFLD) onset and worsening. The investigators aimed to evaluate the effects of confinement-related lifestyle changes experienced during…
- Trial name
- NCT05416970
- Testing
- SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES
- Where
- Italy
- Volunteers
- 122 people
- Sponsor
- University of Campania Luigi Vanvitelli
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Prebiotics in Patients With Non-alcoholic Liver Disease
The purpose of this present study is to evaluating whether prebiotics - ITF (Inulin/OFS 75/25) is effective in treating patients with non-alcoholic liver disease.
- Trial name
- NCT02642172
- Testing
- ITF (Inulin/OFS 75/25)
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Kaplan Medical Center
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Nonalcoholic Fatty Liver
Crassostrea Gigas for Liver Health
This study aimed to observe whether a hydrolyzed oyster extract improves liver health in participants whose alanine transaminase (ALT) levels are1-3 fold above the normal.
- Trial name
- NCT02992470
- Testing
- Hydrolyzed oyster extract
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Korean Medicine Hospital of Pusan National University
Nonalcoholic Steatohepatitis (NASH)
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics
This study will evaluate the safety and tolerability of escalating single- and multiple-oral doses of cilofexor, and characterize the single- and multiple-dose pharmacokinetics (PK) of cilofexor.
- Trial name
- NCT02654002
- Testing
- Cilofexor
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- NCT06493253
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- United States
- Volunteers
- 1,519 people
- Sponsor
- PharmaNest, Inc
Coagulation Protein Disorders, Blood Loss, Surgical
Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)
Beriplex® P/N is made from human plasma (the liquid part of the blood) and contains the coagulation factors II, VII, IX and X which are important for blood clotting (coagulation).
- Conditions
- Coagulation Protein Disorders, Blood Loss, Surgical, Perioperative Care
- Trial name
- NCT01053169
- Testing
- Beriplex® P/N, Fresh Frozen Plasma (FFP) and Beriplex® P/N, Fresh Frozen Plasma
- Where
- 6 sites in United Kingdom
- Volunteers
- 445 people
- Sponsor
- CSL Behring
Ascites Hepatic, Cirrhosis and Chronic Liver Disease
Evaluation of 'Melody' Paracentesis Device for Ascites Therapy
Ascites is the accumulation of fluid inside the abdomen. This can happen when the liver fails due to a substantial amount of scarring (cirrhosis).
- Trial name
- EMPATHY (NCT03191851)
- Testing
- standard device, Melody Device, Melody Device with Pump
- Where
- United Kingdom
- Volunteers
- 101 people
- Sponsor
- University of Nottingham
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or…
- Trial name
- MAESTRO-NASH (NCT03900429)
- Testing
- MGL-3196, Liver Biopsy
- Where
- 247 sites in United States, Australia and 14 more
- Volunteers
- 1,759 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Visceral Obesity, Non-alcoholic Fatty Liver
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
This study aims to evaluate the effect of daily intake of a specific combination of different natural histidine-related amino acids in combination with dietary recommendations, in the reduction of visceral fat, as well as their…
- Conditions
- Visceral Obesity, Non-alcoholic Fatty Liver, Postmenopausal
- Trial name
- FATHIS+ (NCT06377631)
- Testing
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
- Where
- 2 sites in Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundació Eurecat
Portal Hypertension
Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension
Portal hypertension is the result of an increased hepatic vascular resistance and portal inflow. The best established method to assess portal pressures is the determination of wedged hepatic venous pressure gradient (HVPG).
- Trial name
- DPH (NCT02975323)
- Testing
- Carvedilol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Aga Khan University
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Study on Risk Factors and Prognosis of MASLD
This longitudinal cohort study will enroll individuals with MASLD (and/or those at risk) and follow them over time to identify clinical and metabolic risk factors for disease progression and to evaluate predictors of long-term…
- Trial name
- NCT07433205
- Where
- China
- Volunteers
- 922 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Chronic HCV Infection, Nonalcoholic Steatohepatitis
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
In the presented project, the role of heme oxygenase 1 and 2 in the procesess associated with fibroproduction in the chronic HCV infection will be studied.
- Trial name
- NCT00842205
- Testing
- pegylated interferon, Ribavarin
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Charles University, Czech Republic
Hepatitis B, HIV Infection
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
This study will evaluate the safety and effectiveness of adding the experimental drug adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in HIV-infected patients with liver cirrhosis.
- Trial name
- NCT00013702
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Diseases
Tissue Models for Liver Disease
The human immune response to bacterial and viral local and systemic infection are fairly well understood, but we lack details on the earliest phases.
- Trial name
- TIMOLD (NCT05255042)
- Testing
- organ and tissue sample collection only
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Leicester
Liver Diseases
The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease
Hospital record of the patients of liver disease admitted from April-May 2021 and April-May 2019 will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of…
- Trial name
- NCT05167305
- Testing
- This is an observational study
- Where
- India
- Volunteers
- 1,316 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Kidney Disease, Liver Disease
Remote Ischemic Preconditioning In Abdominal Organ Transplantation
Does remote ischemic preconditioning (RIPC) induced by a brief period of occlusion of blood flow to the lower extremity prior to organ recovery in deceased donors, improve short and long term outcomes after transplantation of…
- Conditions
- Kidney Disease, Liver Disease, Pancreas Disease
- Trial name
- RIPCOT (NCT00975702)
- Testing
- RIPC by Inflation of Pneumatic Tourniquet
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Non Alcoholic Fatty Liver, Obesity
Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.
Effect of oral selected Probiotics (PRO) and/or Berberine (BBR) supplementation on hepatic steatosis markers, cardiometabolic profile, and gut microbiota profile in the non-alcoholic fatty liver (NAFL) - a randomized double-blind…
- Trial name
- NCT05523024
- Testing
- Probiotic, Berberine, Probiotc and Berberine
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- Poznan University of Medical Sciences
Cholangiocarcinoma, Hepatobiliary Neoplasm
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer
- Trial name
- NCT01151761
- Testing
- Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University